- Sector
- Healthcare
- Industry
- Biotechnology
Highlights
- Market Cap
- $1.89M
- EPS (TTM)
- $0.04
- PE Ratio
- 97.93
- Gross Profit (TTM)
- -$5.31K
- EBITDA (TTM)
- -$6.74M
- Year Range
- $1.83 - $28.03
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NCEL Performance Chart
NewcelX Ltd (NCEL) is up 120.5% since the beginning of the year. At $4 per share, NCEL is trading 85.1% below its 52-week high of $28. Investors who bought $1,000 worth of NCEL shares 5 years ago would now be looking at an investment worth $3.
Loading charts...
Returns By Period
NewcelX Ltd (NCEL) has returned 120.53% so far this year and -80.05% over the past 12 months.
NewcelX Ltd
- 1D
- 1.45%
- 1M
- 29.72%
- 6M
- 91.32%
- YTD
- 120.53%
- 1Y
- -80.05%
- 3Y*
- -77.34%
- 5Y*
- -67.91%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.42%
- 1M
- 1.94%
- 6M
- 8.74%
- YTD
- 10.66%
- 1Y
- 21.02%
- 3Y*
- 19.50%
- 5Y*
- 11.63%
- 10Y*
- 13.41%
NCEL Monthly Returns History
Based on dividend-adjusted daily data since Jan 29, 2021, NCEL's average daily return is -0.11%, while the average monthly return is -3.76%.
Historically, 39% of months were positive and 61% were negative. The best month was Apr 2026 with a return of +108.0%, while the worst month was Oct 2025 at -60.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, NCEL closed higher 43% of trading days. The best single day was Mar 12, 2021 with a return of +107.5%, while the worst single day was Mar 20, 2024 at -41.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 36.84% | 11.54% | -26.90% | 108.02% | -20.18% | 3.98% | 14.48% | 120.53% | |||||
| 2025 | 18.01% | -26.10% | -16.30% | -4.42% | 49.46% | 31.82% | -36.55% | 15.22% | -13.68% | -60.16% | -44.99% | -52.62% | -91.00% |
| 2024 | -22.02% | -15.91% | -53.46% | -22.39% | 0.93% | 53.83% | 1.15% | -32.04% | -14.99% | -28.40% | -6.89% | -37.57% | -91.06% |
| 2023 | 0.78% | 10.00% | 6.29% | -12.50% | -20.30% | 3.77% | -15.65% | 9.94% | -31.37% | -5.71% | -36.38% | 40.49% | -54.27% |
| 2022 | -18.92% | 32.22% | 18.49% | -39.21% | -20.66% | -13.65% | -37.02% | 33.83% | 25.28% | -15.73% | 58.85% | 55.42% | 16.22% |
| 2021 | -20.17% | -1.04% | 41.26% | -9.41% | -5.74% | -8.99% | -17.20% | -5.00% | 1.21% | -13.60% | -6.02% | -45.32% | -69.34% |
Benchmark Metrics
NewcelX Ltd has an annualized alpha of -29.81%, beta of 0.51, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 29, 2021.
- This stock participated in 203.43% of S&P 500 Index downside but only -106.36% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.51 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -29.81%
- Beta
- 0.51
- R²
- 0.00
- Upside Capture
- -106.36%
- Downside Capture
- 203.43%
Return for Risk
Risk / Return Rank
NCEL ranks 13 for risk / return — in the bottom 13% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NewcelX Ltd (NCEL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NCEL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.35 | ||
| Sortino ratioReturn per unit of downside risk | -3.43 | ||
| Omega ratioGain probability vs. loss probability | 0.85 | 1.30 | -0.45 |
| Calmar ratioReturn relative to maximum drawdown | -0.87 | 2.28 | -3.15 |
| Martin ratioReturn relative to average drawdown | -1.08 | 9.88 | -10.97 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NewcelX Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NewcelX Ltd was 99.92%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current NewcelX Ltd drawdown is 99.82%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.92%Mar 2026 | 5y 16d | — | 5y 4moMar 2021 - now |
2021 bear market2021 | -37.02%Mar 2021 | 1mo 5d | 7d | 1mo 12dJan 2021 - Mar 2021 |
Drawdown Indicators
| NCEL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.92% | -56.78% | -43.14% |
Max Drawdown (1Y)Largest decline over 1 year | -93.26% | -9.10% | -84.16% |
Max Drawdown (3Y)Largest decline over 3 years | -99.61% | -18.90% | -80.71% |
Max Drawdown (5Y)Largest decline over 5 years | -99.85% | -25.43% | -74.42% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.82% | -0.45% | -99.37% |
Average DrawdownAverage peak-to-trough decline | -84.58% | -10.71% | -73.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 75.12% | 2.09% | +73.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NewcelX Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NewcelX Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for NCEL, comparing it with other companies in the Biotechnology industry. Currently, NCEL has a P/E ratio of 97.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NCEL
Add NewcelX Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NCEL